Objective: The aim of the present study was to evaluate the incidence of lymphedema and cancer recurrence rate in patients with cervical cancer who undergo sentinel lymph node (SLN) biopsy alone in the absence of SLN metastases. Patients and Methods: The study included 35 consecutive patients with cervical cancer scheduled for radical hysterectomy at Tohoku University Hospital between May 2006 and July 2009. All patients had International Federation of Gynecology and Obstetrics stages IA1 to IIA1 disease. Patients in whom SLNs were detected unilaterally or not detected and/ or whose lymph nodes were diagnosed intraoperatively as positive metastasis underwent systemic pelvic lymphadenectomy. Patients who were found negative for SLN metastasis did not undergo further pelvic lymphadenectomy. Results: The mean number of detected SLNs was 4.1 (range, 1Y11). True lymph node metastasis could be detected in 11 (31%) of the 35 cases. Intraoperative frozen section identified correctly in 8 of 11 metastatic patients. Twenty-three patients underwent SLN biopsy alone without systematic pelvic lymphadenectomy. None of the 23 patients diagnosed with negative SLNs have experienced a lymph node recurrence in the pelvic cavity. New symptomatic lower extremity lymphedema was identified in 2 (8.7%) of the 23 patients who underwent SLN biopsy alone and in 5 (42%) of 12 patients who underwent systematic lymphadenectomy. Conclusion: Radical hysterectomy with SLN biopsy alone seems to be a safe and effective strategy for detection of lymph node metastasis and for reducing the number of patients with lower extremity lymphedema, but a more convenient and sensitive procedure for intraoperative diagnosis needs to be established.
T he number of young women with cervical cancer has increased in recent years. 1 Such patients must survive with treatment-associated sequelae for a long time. Therefore, prevention of some of these sequelae, particularly lymphedema, is important in this patient population. 2 In breast cancer, the rate of postoperative complications including lymphedema has been reported to significantly decrease in patients who undergo sentinel lymphadenectomy alone. 3 The feasibility of sentinel lymph node (SLN) mapping for staging of gynecological malignancies has been well explored in vulvar cancer, 4, 5 cervical cancer, 6Y10 and endometrial cancer. 11Y13 In cervical cancer, a review of 842 patients in whom SLN mapping was performed revealed a 97% detection rate and 92% sensitivity when a combined method (both radioactive tracer and blue tracer) was used. 8 Moreover, multicenter studies have reported that SLN detection is fully reliable when SLNs are detected bilaterally. 7, 10 In breast cancer, a randomized controlled study demonstrated that SLN biopsy is an effective and well-tolerated procedure.
14 However, the rates of cancer recurrence and lymphedema occurrence in patients with SLN-negative cervical cancer who do not undergo further pelvic lymphadenectomy are thus far unknown.
Our previous report described the use of an SLN identification technique using technetium-99mTc phytate and patent blue dye injection in cervical cancer. 6 Moreover, another study demonstrated that only SLNs, and not nonsentinel nodes, had micrometastases and/or isolated tumor cells (ITCs) in patients with cancer cells. 15 The aim of the present study was to evaluate the incidence of lymphedema and cancer recurrence rate in patients who undergo SLN biopsy alone in the absence of SLN metastases.
MATERIALS AND METHODS

Patients
Consecutive patients with cervical cancer included in this study were treated at Tohoku University Hospital between May 2006 and July 2009 after signing a full, written, informed consent form. The study protocol was approved by the Ethics Committee of Tohoku University Graduate School of Medicine, Sendai, Japan (2005Y279). Patients with International Federation of Gynecology and Obstetrics stage IA1 (with severe lymphovascular space involvement), IA2, IB1, or IIA1 disease were eligible for study participation. Exclusion criteria included evidence of lymph node metastases and/or tumors more than 3 cm on magnetic resonance imaging (MRI) and/ or computed tomography at preoperative evaluation. Patients underwent laparotomy (radical hysterectomy for stages IA2 to IIB1 disease and extended hysterectomy for stage IA1 disease, with or without pelvic lymphadenectomy) with SLN biopsy. Patients in whom SLNs were detected unilaterally or not detected and/or who had a diagnosis of positive lymph node metastasis intraoperatively underwent systemic pelvic lymphadenectomy. Patients who were found negative for SLN metastasis did not undergo further pelvic lymphadenectomy. Adjuvant therapy was performed according to final pathological results after surgery. The present study flow is summarized in Figure 1 .
SLN Detection Procedure
The SLN detection procedure described in our previous report 6 was followed. On the day before surgery, lymphoscintigraphy was performed with injection of 0.4 mL of fluid containing 60 MBq 99mTc-labeled phytate (DRL, Tokyo, Japan) into the cervix at the 3-, 6-, 9-, and 12-o'clock positions (0.1 mL per injection site). These procedures were conducted in the nuclear medicine department. Dynamic lymphoscintigraphy lasted for approximately 1 hour. The first lymphoscintigram was taken at this time, and the second lymphoscintigram was taken the next morning just before the patient entered the operating room.
After the abdominal cavity was opened, 4.0 mL of blue dye (patent blue violet; Sigma, St Louis, MO) was injected into the cervix (1.0 mL per injection site) at the same sites as the radioisotope-phytate solution. Before lymphadenectomy was started, radioactive and/or blue lymph node(s) were located using a gamma-detecting probe (Navigator GPS, RMD; Watertown, MA) and by inspection, respectively. When the gamma-detecting probe registered counts of more than 10-fold higher than background radiation levels, the node was considered radioactive. All radioactive and blue nodes were considered SLNs. After SLN biopsy was performed, the area of lymphadenectomy was scanned with the probe to confirm that no radioactive tissue remained. One surgeon conducted all the sentinel node biopsies and other surgical procedure. We had experienced SLN biopsies for more than 50 patients with cervical cancer for 5 years before the present study. Areas of detection of SN are expressed using international surgical classification as those proposed by Cibula and Abu-Rustum. 16 
Pathological Examination
Frozen section analysis of detected SLNs was performed intraoperatively. Each SLN was examined using step sectioning at 2-mm intervals parallel to the short axis of the node and examined with hematoxylin and eosin (H&E) staining. The remaining tissue was fixed in formalin and embedded in paraffin for routine histological analysis.
All surgically removed non-SLNs were examined histopathologically using routine H&E staining. After SLNs were reexamined and diagnosed as negative for metastasis by routine H&E staining, the blocks were cut at 0.1-mm intervals, and slides were immunostained with an antibody directed against cytokeratin (AE1/AE3, Dako, Japan), expression of which is a characteristic of metastatic cancer cells.
Isolated tumor cells were defined as metastases measuring 0.2 mm or less. Micrometastases were defined as tumors ranging from 0.2 to 2 mm. Tumors more than 2 mm were defined as macrometastases. 17 
Follow-up
Patients were followed up every 1 to 3 months for 4 years and then every 6 months. At each follow-up visit, pelvic examination, ultrasonography (USG), and vaginal cytology were performed. Computed tomography and/or MRI were performed every 1 year or in the case of clinical suspicion. The presence of lymphedema and/or phlegmon was documented, and those symptoms were evaluated through the follow-up period. Lower extremity lymphedema was judged based on the consensus document of the International Society of Lymphology. 18 Stage I represents swelling caused by fluid relatively high in protein content and subsides with limb elevation. Pitting may occur. Stage II signifies that limb elevation alone rarely reduces tissue swelling, and pitting is manifest. Late in stage II, the limb may or may not pit as tissue fibrosis supervenes. Stage III encompasses lymphostatic elephantiasis, where pitting is absent and skin changes such as acanthosis, fat deposits, and warty overgrowths develop. In the present study, lymphedema was defined as stage II or III cases related to lymphadenectomy.
Statistical Analyses
The Fisher exact test was used to test differences between the methods for statistical significance in case of 2 Â 2 tables and the W 2 test in case of 2 Â J tables. P G 0.05 was considered statistically significant.
RESULTS
Patients' Characteristics
Patients' ages ranged from 24 to 62 years (median, 39 years). Conization was performed in 18 patients before radical hysterectomy. Histological analysis revealed squamous cell carcinoma in 29 patients and adenocarcinoma in 6 patients. International Federation of Gynecology and Obstetrics stages included IA1 (n = 2), IA2 (n = 2), IB1 (n = 29), and IIA1 (n = 2). Only 2 patients had a tumor of more than 2 cm in diameter: patient 10 had a tumor with a diameter of 3 cm, whereas the diameter of the tumor in patient 12 was determined as 4 cm after surgery.
Detection Rates and Sites of SLNs
Results of SLN detection are summarized in Table 1 . The mean number of detected SLNs was 4.1 (range, 1Y11).
Most patients had an SLN in one of the following 3 sites: obturator region (62 nodes), external iliac region (33 nodes), and internal iliac region (26 nodes). Intraoperative scanning with a gamma probe detected at least one hot spot in all patients (100%). Bilateral SLNs were detected in 30 (86%) of the 35 patients.
Lymph Node Metastasis
Sizes and locations of lymph node metastasis are summarized in Table 1 . Sentinel lymph nodes in 9 patients were diagnosed as positive intraoperatively, but the SLN in case 17 was determined to be false positive. The histologic classification of case 17 was adenocarcinoma, and endosalpingiosis was misdiagnosed as a metastasis in frozen sections. Sentinel lymph node metastasis was detected postoperatively in case 11 (squamous cell carcinoma) and case 22 (adenocarcinoma) as micrometastasis and in case 7 as ITCs of squamous cell carcinoma. Sentinel lymph node micrometastasis was found by postoperative reexamination of intraoperative frozen sections in case 11 and by postoperative reexamination using sectioning at 0.1-mm intervals in case 22. The left external iliac lymph node was swollen, and metastasis was detected by intraoperative biopsy in case 18. No SLN could be detected on the left side of the pelvic cavity, but micrometastasis was detected in the right external SLN. True lymph node metastasis was detected in 11 (31%) of the 35 cases. Intraoperative frozen section identified correctly in 8 of the 11 patients with metastasis.
Surgical Procedure and Adjuvant Therapy
Surgical procedures and adjuvant therapy are summarized in Table 2 . Twenty-three patients underwent SLN biopsy alone without systematic pelvic lymphadenectomy. Overall, 7 patients with positive SLN metastasis and 5 patients without bilateral SLN detection underwent systematic pelvic lymphadenectomy.
Nine of the 23 patients who underwent SLN biopsy alone received adjuvant chemoradiation or radiation therapy, whereas 8 of 12 patients who underwent systematic lymphadenectomy received adjuvant chemoradiation therapy. Concurrent chemoradiotherapy was indicated to patients with positive lymph node metastasis and/or with severe lymphovascular invasion, and radiation therapy was indicated for patients with deep stromal invasion in the present study.
The median operation time was 190.5 minutes (range, 153Y302 minutes) in the systematic lymphadenectomy group and 198 minutes (range, 127Y286 minutes) in the SLN biopsy alone group. The median amount of blood loss was 598.5 mL (range, 86Y1142 mL) in the systematic lymphadenectomy group and 415 mL (range, 152Y1576 mL) in the SLN biopsy alone group.
Follow-Up
The median follow-up period for all 35 patients was 49 months (range, 15Y70 months), with a minimum of 32 months in survivors. Of the 35 patients, 34 are alive and 31 have experienced no recurrence. None of the 23 patients with negative SLNs have experienced a lymph node recurrence in the pelvic cavity, although 3 patients have experienced a cancer recurrence: lung metastasis in patients 13 and 26 and vaginal metastasis in patient 19; both of these patients received additional therapy and are currently alive with no evidence of disease. Patient 12 underwent standard radical hysterectomy owing to the presence of SLN metastasis detected intraoperatively and subsequently received adjuvant chemoradiation therapy; however, she experienced recurrence and died 15 months after surgery. Therapeutic characteristics and adverse effects are summarized in Table 2 . New symptomatic lower extremity lymphedema was identified in 2 (8.7%) of 23 patients who underwent SLN biopsy alone. In contrast, 5 (42%) of 12 patients with systematic lymphadenectomy experienced leg edema. The incidence of lower extremity lymph edema was significantly lower (P = 0.03) in the SLN biopsy alone group 
DISCUSSION
Sentinel lymph node dissection has become a standard of care in patients with breast cancer and melanoma. 14, 19 In cervical cancer, several reports have evaluated the feasibility of SLN biopsy, and the detection rate and accuracy results were not inferior to those of breast cancer. 6Y10 We also previously studied the feasibility of SLN detection in patients with cervical cancer and reported that micrometastases could be detected by step-serial sectioning with cytokeratin immunostaining. 6, 15 To our knowledge, only one prospective study about patients with cervical cancer managed using SLN biopsy without further systematic pelvic lymphadenectomy has been published, but it did not report on lymphedema incidence. 9 The present study is the first prospective study to evaluate the safety of a strategy in which patients without SLN metastasis undergo no further pelvic lymphadenectomy, and to compare 
the incidence of lymphedema between patients who undergo SLN biopsy alone versus SLN biopsy followed by pelvic lymphadenectomy. An AGO group study reported a 94% SLN detection rate in patients with tumors less than 2 cm. 7 Only 2 patients had a tumor with a diameter of more than 2 cm in our study, in whom the SLN detection rate was 100% and bilateral detection rate was 84%. Patients with such a small tumor size may be adequately treated with SLN biopsy.
In the present study, patients in whom SLNs could not be detected bilaterally and/or who were diagnosed with positive lymph node metastasis intraoperatively underwent systematic (bilateral) pelvic lymphadenectomy. The previous literature has indicated that no false-negative results have been observed in patients in whom SLNs were identified bilaterally. 10 In patient 18, only the right external SLN could be detected, in which micrometastasis was identified, but a lymph node with macrometastasis on the left side was not recognized as an SLN. The other 4 patients in whom unilateral SLNs were detected did not have lymph node metastasis in non-SLNs.
To date, even if patients have proven to have swollen and/or metastatic lymph nodes intraoperatively and the therapeutic efficacy of removal of metastatic SLNs has been unclear, we have performed radical hysterectomy with pelvic lymphadenectomy. Although avoidance of unilateral pelvic lymphadenectomy in patients without SLN metastasis on the same side may be safe, this remains unclear. We classified patients in whom SLNs could not be detected bilaterally as failures and thus moved forward with bilateral lymphadenectomy. Further study to identify patients in whom unilateral pelvic lymphadenectomy can be avoided is required.
Lymph node metastasis was detected in 11 (31%) of the 35 patients in the present study. Ultrastaging using SLN biopsy has been previously reported to improve identification of lymph node metastasis in patients with cervical cancer 20 ; the lymph node metastasis detection rate has been reported to be almost 20%. 21 Moreover, the detection rate of micrometastasis has been reported to be higher than that of SLN biopsy. 21 The present study included 4 patients with micrometastasis and 2 patients with ITCs. In patients with squamous cell carcinoma, all metastases except for ITCs should be identified using intraoperative frozen sectioning. Intraoperative 2-mm interval step-serial sectioning in squamous cell carcinoma is considered a safe method for identifying lymph nodes with more than 0.2-mm metastases, although intraoperative diagnosis is not precise and not recommended by some researchers. 22 In contrast, benign type inclusions, such as endosalpingiosis and endometriosis, are frequently encountered in pelvic lymph nodes of women; and endosalpingiosis has been reported to lead to misdiagnosis in adenocarcinoma cases. 23 Moreover, sensitivity to radiation therapy is relatively high in patients with squamous cell carcinoma compared to those with adenocarcinoma. 24 Thus, careful diagnosis is necessary in cervical adenocarcinoma. It may be safe to recommend avoiding systematic pelvic lymphadenectomy only in patients with squamous cell carcinoma.
In the present study, each SLN was examined using step sectioning at 2-mm intervals parallel to the short axis of the node. The improvement in detection of lymph node metastasis compared to that of past reports may be that a larger number of frozen sections were diagnosed intraoperatively. Whereas the detection rate of lymph node metastasis has improved, the workload of pathologists has also increased. Thus, the ability to perform the present intraoperative diagnostic procedure may be limited in some institutions. Other convenient strategies for intraoperative diagnosis, such as mRNA detection and one-step nucleic acid amplification techniques, need to be established. 25 Regardless of the method used, SLN diagnosis should be performed by a fully trained pathologist.
In the present study, micrometastasis was detected in 4 patients, macrometastasis was detected in 5 patients, and ITCs were detected in 2 patients. No patients, except for patients 12, had lymph node metastasis in a non-SLN among the 8 cases diagnosed as positive SLN metastasis intraoperatively. Patient 12 had SLN metastasis at the right obturator basin but also had a macroscopically swollen and metastatic lymph node at the right external iliac basin that was not detected as a SLN. We do not know whether a strategy is feasible in which systematic lymphadenectomy is skipped and adjuvant therapy is administered in cases with micrometastasis only. Future evaluation is required to confirm the safety of this procedure.
New symptomatic lower extremity lymphedema was identified in only 2 patients (patients 11 and 31) with SLN biopsy alone. The incidence of lower extremity lymph edema was significantly lower in the SLN biopsy alone group than in the systematic lymphadenectomy group. Four SLNs (one right external node, one obturator node, and 2 left external nodes) were removed, and no further radiation therapy was needed for patient 11. Two SLNs (bilateral external nodes) were removed and chemoradiation therapy was performed on patient 31 with parametrial lymphovascular invasion. In breast cancer, lymphedema appeared in 5% of the SLN biopsy alone patients, compared with 16% of the patients with systematic lymphadenectomy. 3 In cervical cancer, we suspect that the occurrence of lymphedema has low frequency but nearly the same frequency as that in the patients with breast cancer even if only SLN biopsy is performed.
In conclusion, SLN biopsy without further pelvic lymphadenectomy in patients with SLN-negative cervical cancer may be safe, particularly in patients with squamous cell carcinoma who can receive potentially effective radiation therapy and effective for preventing extremity lymphedema. A more convenient and sensitive procedure for intraoperative diagnosis needs to be established. The 5-year survival rate is high (approximately 95%) in patients with IB1 cervical cancer who underwent radical hysterectomy with systematic lymphadenectomy. Such patients represent the target of SLN biopsy. If a randomized trial is powered to test noninferiority (a difference in survival of 5% between the SLN only and full lymph node dissection groups at 5 years), more than 640 patients are required to obtain 80% power with a 1-sided > equal to 0.05. Therefore, a randomized controlled trial with patient survival as an outcome would not be feasible; rather, observational prospective specialized multicenter trials are required in the future. Moreover, lymphedema occurrence or lymph node metastases seem to be useful end points. Our present study was a nonrandomized study, and the number of evaluable patients was small. The use of SLN biopsy without full lymph node dissection may be demonstrated in the randomized study (Ganglion Sentinell dans Cancer du Col 2) that is ongoing in France, in which incidence of adverse events is the primary outcome.
